Effects of AZD1775 on the PK Substrates for CYP3A, CYP2C19, CYP1A2 and on QT Interval in Patients With Advanced Cancer

NCT03333824 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Solid Tumours

Interventions

DRUG: CYP1A2 (caffeine)
DRUG: CYP2C19 (omeprazole)
DRUG: CYP3A (midazolam)
DRUG: Kytril (granisetron)
DRUG: Wee-1 kinase inhibitor AZD1775

Sponsor

AstraZeneca

Collaborators

[object Object]